Aprea Therapeutics APRE 深 滬
等待開盤 03-26 09:30:00 美东时间
0.671
-0.003
-0.39%
華盛通- 最 高0.6988
- 今 開0.665
- 成交量 1.43万股
- 最 低 0.665
- 昨 收 0.6736
- 總市值 768.37万
- 52周最高 2.22
- 市盈率 靜 --
- 換手率 0.12%
- 52周最低 0.548
- 委 比 90.24%
- 總股本 1145.11万
- 歷史最高 1062.20
- 量 比 0.24
- 振 幅 5.02%
- 歷史最低 0.548
- 每 手 1
- 風險率 0.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aprea Therapeutics Q4 EPS $(0.32) Misses $(0.30) Estimate, Sales $3.337K Down From $205.817K YoY
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.30) by 5.61 percent. This is a 34.69 percent increase over losses of $(0.49) per share
03-16 20:11
Aprea Therapeutics Q4 net loss narrows as R&D costs fall
Aprea Therapeutics Q4 net loss narrows as R&D costs fall Overview Oncology drug developer's Q4 net loss narrowed from prior year Q4 R&D expenses fell due to lower clinical trial costs and fewer personnel expenses Outlook Company expects cash and equivalents to fund operations into Q1 2027 Result Dri
03-16 20:09
Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars
Aprea Therapeutics shares rise after promising Phase 1 trial results with APR-1051 in cancer treatment.
02-19 03:02
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
Aprea Therapeutics announced preliminary data from its Phase 1 trial of APR-1051, a WEE1 kinase inhibitor, in patients with advanced solid tumors. At the 220 mg dose, a patient with advanced endometrial cancer achieved a 50% tumor reduction and significant CA-125 biomarker decline (from 362 U/mL to 47 U/mL). This marks the second confirmed partial response in patients with PPP2R1A mutations, supporting APR-1051's potential efficacy in this popula...
02-18 13:00
Most and least shorted healthcare stocks with up to $2B market cap
Short interest in small-cap healthcare surged toward the end of January, centering heavily on the biotechnology sector. Data as of January 30 shows that KalVista (KALV) and Intellia (NTLA) have become...
02-17 02:05
美股大行评级 | 安森美半导体获多家大行调目标价；BD医疗、Dynatrace、Monday、Regenxbio遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持内克塔治疗"买入"评级，目标价从135美元升至165美元；BTIG：维持内克塔治疗"买入"评级，目标价从118美元升至151美元
02-11 11:02
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $7
Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $11 to $7.
02-10 22:36
Aprea Therapeutics CFO John P. Hamill Acquires Common Shares
Aprea Therapeutics CFO John P. Hamill Acquires Common Shares John P. Hamill, Senior Vice President, Chief Financial Officer, and Principal Financial and Accounting Officer of Aprea Therapeutics Inc., has reported the acquisition of common shares of the company. The full filing can be accessed throug
02-03 05:06
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Vyome Holdings (NASDAQ:HIND) stock increased by 16.1% to $2.23 during ...
02-02 20:05
BUZZ-U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer
BUZZ-U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks fell on Friday after President Donald Trump nominated for
01-31 02:38
